The Culprit Impeding Drug Competition Is Not Who The Feds Expected

News
Written By THG Digital

PACIFIC RESEARCH INSTITUTE

If any industry deserves to face antitrust scrutiny, it’s this one. Putting a stop to PBMs’ anticompetitive practices would be far more fruitful than imposing new price controls or other regulations on manufacturers.

Read more here.

THG Digital
Previous

The Big Beautiful Bill Fixes One Drug Problem—But Highlights An Even Bigger One
Next

Buchanan, Arrington Lead Letter on Foreign Freeloading on American-Financed Innovation to U.S. Trade Representative